• Patients diagnosed with Diffuse Large B Cell Lymphoma, not otherwise specified (DLBCL, NOS) and other aggressive large B-cell lymphomas, according to current WHO/ICC diagnostic principles.
* Histopathological diagnosis obtained by excisional biopsy, core biopsy or adequate tissue biopsy.
* Availability of FFPE tissue blocks with sufficient viable tumor for immunohistochemical (IHC) staining.
* Diagnostic tissue obtained before the initiation of definitive systemic therapy.
* Available minimum clinical data: age, sex, date of diagnosis, treatment status, and follow-up/survival status.
* For survival analysis: cases with documented follow-up date or date of death/progression.
You may not be if
• Inadequate tissue, exhausted block or severe fixation/processing artifact preventing reliable IHC interpretation.
* Extensive necrosis, crush artifact or decalcification artifact in the only available diagnostic tissue.
* Relapse biopsy after chemotherapy without available pretreatment diagnostic tissue.
* Primary Hodgkin lymphoma, indolent B-cell lymphoma without transformation, T-cell lymphoma or metastatic non-lymphoid malignancy.
* Cases lacking essential clinical outcome data for prognostic analysis (except for descriptive staining analysis).
* HIV-associated, post-transplant or primary CNS DLBCL may be excluded or analyzed separately due to distinct biology.
Clareo Health | Tumour Immune and Ki-67 Scoring Methods as Prognostic Biomarkers in Diffuse Large B-cell Lymphoma and Aggressive B-cell Lymphomas
